Immune Checkpoint Blockade: The New Big Idea In Cancer
Biologics that target immune checkpoints co-opted by cancer resistance have been significantly de-risked by the success of Bristol’s immunotherapy Yervoy and the progress of its Phase III candidate nivolumab. With six companies now testing candidates in the clinic, the class promises to have a big impact on oncology over the next several years, with the possibility of a next-generation approval by 2015.
You may also be interested in...
Even given huge optimism to date for immunotherapy checkpoint inhibitors, the rapid approval of Bristol’s PD-1 inhibitor nivolumab in squamous type lung cancer is a welcome surprise and bodes well for the class in the future.
Nivolumab investigator, ASH presidential symposium speaker and translational biologist Margaret Shipp explains in an interview why PD-1 blockade might be better in Hodgkin lymphoma than PD-L1 inhibition, and contemplates the future in other blood diseases.
PharmAsia News brings highlights from Japan’s week of earnings presentations.